29 March 2017
READING, UNITED KINGDOM (29 March 2017) — ConvaTec Group Plc ("ConvaTec" or the "Company") announces that further to the sale of shares in the Company by Nordic Capital and Avista (as defined below), which they have announced separately today, Thomas Vetander and Kunal Pandit who are nominated directors of Nordic Capital and Avista, respectively, have tendered their resignations from the Board, effective from 31 March 2017.
Bobby Leach, VP Group Corporate Affairs, ConvaTec +44 (0)7770 842 226
Kirsty Law, Director Investor Relations +44 (0)7470 909 582
Rebecca Fitchett +44 (0)207 251 3801
ConvaTec is a global medical products and technologies company focused on therapies for the management of chronic conditions, with leading market positions in advanced wound care, ostomy care, continence and critical care, and infusion devices. Our products provide a range of clinical and economic benefits including infection prevention, protection of at-risk skin, improved patient outcomes and reduced total cost of care. To learn more about ConvaTec, please visit www.convatecgroup.com where a copy of this announcement can also be found.
“Nordic Capital” refers to Nordic Capital VII Limited, acting in its capacity as General Partner of Nordic Capital VII Alpha, L.P. and Nordic Capital VII Beta, L.P. together with associated co-investment vehicles and Nordic Capital VI Limited, acting in its capacity as General Partner of Nordic Capital VI Alpha, L.P. and Nordic Capital VI Beta, L.P. together with associated co-investment vehicles.
“Avista” is the limited liability companies and limited partnerships managed by Avista Capital Managing Member, LLC with interests in ConvaTec, including Avista Capital Partners LP, Avista Capital Partners II LP and their affiliated funds and co-invest vehicles.